Optimizing Care for Cancer Survivors With Depression: Project 3
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this research study is to evaluate different depression treatment approaches among cancer survivors. A cancer survivor is defined as anyone who is living and has been diagnosed with cancer. Participants will be randomly assigned to either receive a mobile app for depression treatment, called "Moodivate", or to receive telehealth depression treatment sessions. Approximately 2/3 of participants enrolled will receive the mobile app and the remaining 1/3 will receive depression treatment via telehealth. Participants that receive Moodivate may later be assigned to also receive depression treatment via telehealth based their response to the Moodivate app. Participants will be asked to either use the Moodivate app and/or receive depression treatment via telehealth for a period of 10 weeks. All participants will be asked to electronic questionnaire measures throughout the study period. Questionnaires will assess symptoms of depression, as well as general experiences using Moodivate and participating in this trial. Participation in this study will take about 24 weeks. Participation in this study may help improve options for emotional wellness for cancer survivors. The greatest risks of this study include frustration, worsening of emotional distress, data breach, and/or loss of confidentiality.
Sponsor: Medical University of South Carolina
You may qualify if…
- ✓ age 18+
- ✓ cancer survivor
- ✓ current elevated depressive symptoms defined per ASCO as a PHQ-9 score ≥ 8
- ✓ not currently receiving psychosocial depression treatment
- ✓ have the ability to complete treatment via telehealth and use Moodivate
- ✓ have a valid e-mail address or text message access (for assessments)
- ✓ English fluency
You may not qualify if…
- ✕ \- Current suicidal ideation at final eligibility screening (PHQ-9 item 9 ≥1)
Where it's recruiting
Charleston
Source: ClinicalTrials.gov · NCT06930729 · last updated 2026-06-10